A detailed history of Opaleye Management Inc. transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Opaleye Management Inc. holds 515,000 shares of RYTM stock, worth $25.4 Million. This represents 5.42% of its overall portfolio holdings.

Number of Shares
515,000
Previous 515,000 -0.0%
Holding current value
$25.4 Million
Previous $22.3 Million 5.24%
% of portfolio
5.42%
Previous 5.43%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$39.12 - $52.44 $3.72 Million - $4.98 Million
-95,000 Reduced 15.57%
515,000 $22.3 Million
Q4 2023

Feb 14, 2024

SELL
$21.39 - $49.64 $919,770 - $2.13 Million
-43,000 Reduced 6.58%
610,000 $28 Million
Q3 2023

Nov 14, 2023

SELL
$15.81 - $27.8 $1.3 Million - $2.28 Million
-82,000 Reduced 11.16%
653,000 $15 Million
Q4 2022

Feb 10, 2023

SELL
$22.21 - $30.25 $1.67 Million - $2.27 Million
-75,000 Reduced 9.26%
735,000 $21.4 Million
Q3 2022

Nov 14, 2022

BUY
$4.3 - $30.85 $1.93 Million - $13.8 Million
448,000 Added 123.76%
810,000 $19.8 Million
Q2 2022

Aug 15, 2022

BUY
$3.12 - $12.25 $1.13 Million - $4.43 Million
362,000 New
362,000 $1.5 Million
Q1 2021

May 18, 2021

SELL
$20.25 - $39.49 $2.33 Million - $4.54 Million
-115,000 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$21.17 - $32.61 $2.43 Million - $3.75 Million
115,000 New
115,000 $3.42 Million
Q1 2020

May 15, 2020

SELL
$13.16 - $22.9 $1.45 Million - $2.53 Million
-110,500 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$19.53 - $25.5 $2.16 Million - $2.82 Million
110,500 New
110,500 $2.54 Million
Q1 2018

May 14, 2018

SELL
$19.9 - $32.25 $762,170 - $1.24 Million
-38,300 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$22.0 - $30.51 $842,600 - $1.17 Million
38,300
38,300 $1.11 Million

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $2.74B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Opaleye Management Inc. Portfolio

Follow Opaleye Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Opaleye Management Inc. with notifications on news.